Prime Medicine is a Cambridge, Massachusetts biotechnology company developing gene editing medicines for genetic diseases. PRME reports earnings on Fri, Nov 6, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 3 dark pool prints.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 25 | Chardan Capital | Maintained | Buy | |
| Aug 25 | Chardan Capital | Maintained | Buy | |
| Aug 19 | BMO Capital | Initiated | Buy | |
| Aug 10 | HC Wainwright & Co. | Reiterated | Buy | |
| Jun 29 | HC Wainwright & Co. | Upgrade | Buy |
Whale Options Flow
90DNo whale options trades in PRME in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PRME is in one of them and how their past PRME trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PRME in an article yet. Here's the latest on the wider market.
About Prime Medicine
Prime Medicine is a biotechnology company based in Cambridge, Massachusetts. It develops gene editing medicines built on a technology called Prime Editing, which is designed to rewrite specific sections of DNA without cutting both strands of the double helix. The company's programs target inherited diseases, with early focus on conditions affecting the liver and lungs and on certain blood disorders. Its medicines are intended for patients with these genetic conditions and the doctors who treat them.
- Headquarters
- Cambridge, MA